Iain R Macpherson
Overview
Explore the profile of Iain R Macpherson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maldonado H, Dreger M, Bedgood L, Kyriakou T, Wolanska K, Rigby M, et al.
Sci Adv
. 2024 Dec;
10(49):eadk9944.
PMID: 39630893
HER2 and αβ integrin are independent predictors of breast cancer survival and metastasis. We identify an αβ/HER2 cross-talk mechanism driving invasion, which is dysregulated in drug-resistant HER2+ breast cancer cells....
2.
Kingston B, Pearson A, Herrera-Abreu M, Sim L, Cutts R, Shah H, et al.
Cancer Discov
. 2023 Nov;
14(2):274-289.
PMID: 37982575
Significance: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding...
3.
Ring A, Kilburn L, Pearson A, Moretti L, Afshari-Mehr A, Wardley A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4751-4759.
PMID: 37773077
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous...
4.
Henriksen P, Hall P, Macpherson I, Joshi S, Singh T, Maclean M, et al.
Circulation
. 2023 Sep;
148(21):1680-1690.
PMID: 37746692
Background: Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by elevations in cardiac troponin concentrations. Beta-adrenergic receptor blocker and renin-angiotensin system inhibitor therapies...
5.
Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, Macpherson I, et al.
Br J Cancer
. 2023 Jul;
129(5):852-860.
PMID: 37468569
Background: The Ibrance® Patient Program was established to provide access to palbociclib for UK National Health Service (NHS) patients with metastatic breast cancer (MBC), pending a funding decision. Methods: Non-interventional...
6.
Morrison A, Marshall-McKenna R, McFadyen A, Hutchison C, Rice A, Stirling L, et al.
Sci Rep
. 2022 Jul;
12(1):11575.
PMID: 35798751
Onycholysis and paronychia has been associated with chemotherapy treatment for women with breast cancer. Our primary aim was to investigate the effectiveness of different topical interventions to ameliorate nail toxicity....
7.
Henriksen P, Hall P, Oikonomidou O, Macpherson I, Maclean M, Lewis S, et al.
Circ Heart Fail
. 2022 Jun;
15(7):e009445.
PMID: 35766037
Background: Anthracyclines are effective cytotoxic drugs used in the treatment of breast cancer and lymphoma but are associated with myocardial injury, left ventricular dysfunction, and heart failure. Anthracycline-induced cardiotoxicity is...
8.
Malorni L, Tyekucheva S, Hilbers F, Ignatiadis M, Neven P, Colleoni M, et al.
Eur J Cancer
. 2022 Feb;
164:39-51.
PMID: 35172272
Background: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent...
9.
Rabas N, Palmer S, Mitchell L, Ismail S, Gohlke A, Riley J, et al.
J Cell Biol
. 2021 Oct;
220(12).
PMID: 34623384
The cystine-glutamate antiporter, xCT, supports a glutathione synthesis program enabling cancer cells to cope with metabolically stressful microenvironments. Up-regulated xCT, in combination with glutaminolysis, leads to increased extracellular glutamate, which...
10.
Kingston B, Cutts R, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al.
Nat Commun
. 2021 Jul;
12(1):4479.
PMID: 34272402
No abstract available.